The Cerebrolysin vascular-dementia evidence — what the systematic reviews actually find

Cerebrolysin occupies an unusual position among research peptides. Unlike Semax, Selank, or Dihexa, it is not a single defined molecule; it is a standardised multi-component preparation. Unlike the other peptides on this site, it has been the subject of substantial Western and international randomised clinical-trial work in addition to the Russian and Eastern European tradition. The clinical-trial body across all indications is the largest in the field, and the meta-analytic literature is correspondingly deeper.

The vascular-dementia indication is one of two principal cognitive areas covered (the other being post-stroke recovery). It is a meaningful test case for Cerebrolysin because vascular dementia is a slowly progressive condition where clinical effects are detectable on standardised cognitive batteries over months of follow-up — a different research design from the acute post-stroke window.

The vascular-dementia Cerebrolysin trial record includes multiple randomised double-blind placebo-controlled studies conducted across Eastern Europe, Russia, and parts of Asia between the mid-1990s and the late 2010s. Sample sizes are larger than the typical Russian peptide trial — several hundred subjects per trial in the larger studies — and the methodology more closely approaches Western standards.

Standard outcome measures across the body include the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog), the Clinical Global Impression of Change (CGI-C), and the Mini-Mental State Examination. Follow-up windows typically extend to 12 or 24 weeks. Cerebrolysin is administered intravenously across treatment cycles, generally 10–30 mL per day over a 10–20 day cycle, sometimes repeated after a washout interval.

Multiple systematic reviews and meta-analyses have synthesised the vascular-dementia trial body, with broadly consistent findings.

On cognitive outcomes, the pooled effect sizes favour Cerebrolysin over placebo, with statistically significant improvements on the ADAS-cog and similar batteries. The magnitude of the effect is modest in absolute terms — typically a few points on the ADAS-cog scale — but consistent across studies and replicable in larger trials.

On global-impression outcomes, the pooled CGI-C effects favour Cerebrolysin, with a higher proportion of subjects classified as improved versus unchanged or worsened in the active arm compared with the placebo arm. The effect is more visible at end-of-treatment than at washout follow-up, consistent with a pharmacological effect that requires continued exposure.

Subgroup analyses suggest stronger effects in moderate rather than mild or severe disease, which is the expected pattern from any therapeutic intervention. Subgroup analyses by sex, age, and concurrent medication are less reliably reported across the trial body.

Independent systematic reviews of the Cerebrolysin vascular-dementia evidence — including reviews approaching Cochrane methodological standards — have generally concluded that the evidence supports a positive cognitive effect, with the methodological quality of the included trials being acceptable but not uniformly excellent.

The standard caveats apply. Heterogeneity between trials is meaningful — different dosing protocols, different study durations, different outcome-measure mixes — and may inflate or distort the pooled effect estimate. Publication bias is plausible given the commercial backing of the trial programme. The trial body is dominated by groups based in jurisdictions where Cerebrolysin is licensed and clinically used, which is unavoidable but worth noting.

The consensus interpretation across independent reviews is that Cerebrolysin has a real and demonstrable cognitive effect in vascular dementia, of modest magnitude, with an acceptable acute safety profile, and with methodological limitations that fall short of the standard required for UK or US regulatory approval but well above the standard typical of the broader research-peptide literature.

The Cerebrolysin evidence base is more substantial than that of any other peptide on this site, and yet the compound remains unlicensed in the UK. The reasons are partly methodological and partly commercial.

Methodologically, the MHRA standard for licensing a medicine for vascular dementia or any other cognitive indication requires evidence that meets specific design and statistical standards that the Cerebrolysin trial body, as a whole, does not uniformly meet. Individual trials within the body do; the pooled record contains too much heterogeneity for a clean submission.

Commercially, the manufacturer has not pursued UK licensing aggressively. The compound is licensed and reimbursed in markets where the commercial return is more straightforward, and the regulatory and commercial investment required to extend that to the UK has not been made.

The result is a compound with substantial international clinical-trial evidence that occupies a regulatory-orphan position in the UK — neither a research chemical in the narrow sense nor a licensed medicine. It can be imported and used under unlicensed-medicines provisions in specific clinical contexts but is not generally available through normal NHS or private-prescription channels.